The research, conducted collaboratively between Cornell University and Weill Cornell Medical College, aims toward tailoring cancer treatment and improving patient survival. Click below to view the presentation.
The U.S. Preventive Services Task Force (USPSTF), a government panel, has issued a recommendation that men should not get routinely screened for prostate cancer using the PSA test. The panel found there is little evidence that testing for PSA, or prostate-specific antigen, saves men’s lives, and that it causes too much unnecessary harm from the treatment of tumors that would never have killed them. The panel concluded that the benefit of screening was outweighed by the potential risks, which include pain, fever, bleeding, infection and problems urinating, resulting from biopsies as well as incontinence and impotence associated with the treatment of tumors that would not have otherwise caused harm. Click here to read more about this on the Prostate Cancer Foundation website, including a dissenting opinion and comments from the Prostate Cancer Foundation.
The USPSTF recommendations in no way affects men who have already been diagnosed with prostate cancer and have received or are currently receiving treatment. PSA remains one of the important tools to follow the results of treatment. We suggest that you discuss your PSA results with your physician.